Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (NYSE: BMY) has expanded its direct-to-patient program by introducing the new BMS Patient Connect platform, offering significant discounts on two key medications. Eliquis (apixaban) will be available at over 40% below list price, while Sotyktu (deucravacitinib) will be offered at more than 80% discount starting January 2026.

The initiative aims to improve medication accessibility and affordability across all 50 states and Puerto Rico for eligible cash-paying patients. Sotyktu, a first-in-class TYK2 inhibitor, is used to treat moderate-to-severe plaque psoriasis in adults. The platform will provide patient support resources and may include additional BMS medicines in the future.

Bristol Myers Squibb (NYSE:BMY) announced positive interim results from its Phase 3 EXCALIBER-RRMM study of iberdomide, a novel CELMoD™ therapy, in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma (RRMM).

The study achieved a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm. The trial will continue to evaluate other endpoints including progression-free survival and overall survival. The safety profile remained consistent with previous studies.

Iberdomide represents the first of a new class of medicines called CELMoDs, potentially establishing a new foundation for multiple myeloma treatment. The company plans to discuss these results with health authorities.

Bristol Myers Squibb (NYSE: BMY) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will host a conference call with the investment community at 8:00 a.m. ET to discuss the results.

Investors and the public can access the live webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the conference concludes on the same platform.

Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The company's Board of Directors has declared a quarterly dividend of $0.62 per share on common stock, payable on November 3, 2025, to stockholders of record as of October 3, 2025.

Additionally, the Board declared a quarterly dividend of $0.50 per share on the company's $2.00 convertible preferred stock, which will be payable on December 1, 2025, to stockholders of record as of November 4, 2025.

Bristol Myers Squibb (NYSE:BMY) announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum scheduled for September 23, 2025. The company will engage in a fireside chat starting at 9:40 a.m. ET.

Investors and the public can access the session through the company's investor relations website at investor.bms.com. An archived recording will be made available after the event's conclusion.

Bristol Myers Squibb (NYSE:BMY) presented results from COLLIGO-HCM, a global real-world study of Camzyos (mavacamten) at the ESC Congress 2025. The study demonstrated the drug's effectiveness in treating obstructive hypertrophic cardiomyopathy (oHCM) across a diverse patient population from four continents.

Key findings showed that 59.9% of patients achieved NYHA class improvement by week 24, with 94.4% of patients reaching NYHA class II or below at 24 weeks. By week 36, 90.3% of patients achieved target LVOT gradients. The safety profile remained consistent with clinical trials, with only 4% requiring temporary interruption due to LVEF concerns.

The study is part of the larger WAYFARER-HCM program, spanning 7 countries and over 3,000 patients, reinforcing Camzyos' position as a standard of care for NYHA class II-III symptomatic oHCM patients.

Bristol Myers Squibb (NYSE: BMY) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for September 8, 2025. The company will engage in a fireside chat starting at 8:30 a.m. ET.

The session will be accessible to investors and the public through the company's investor relations website at investor.bms.com, with an archived recording available after the event.

Bristol Myers Squibb (NYSE: BMY) announced new clinical and real-world data presentations for its cardiovascular portfolio at the upcoming European Society of Cardiology Congress 2025 in Madrid. The presentations will focus on Camzyos (mavacamten), the first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Key highlights include real-world outcomes from COLLIGO-HCM study across five countries, a pooled analysis of four Phase 3 studies on Camzyos monotherapy, and topline results from ODYSSEY-HCM, the largest Phase 3 trial in non-obstructive HCM patients. The congress will take place from August 29 to September 1, 2025, featuring multiple presentations on Camzyos's efficacy, safety, and real-world effectiveness.

Bristol Myers Squibb (NYSE: BMY) and SystImmune announced that their drug izalontamab brengitecan (iza-bren) has received Breakthrough Therapy Designation (BTD) from the FDA for treating advanced EGFR-mutated non-small cell lung cancer (NSCLC) in patients who progressed after EGFR TKI and platinum-based chemotherapy.

Iza-bren is a first-in-class bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3 receptors. The BTD was based on promising efficacy and safety data from three ongoing clinical trials: BL-B01D1-101, BL-B01D1-203 (in China), and the global BL-B01D1-LUNG-101 study.

This development addresses a significant unmet need, as NSCLC represents 80% of lung cancer cases, with 10-15% of Western and up to 50% of Asian patients having EGFR mutations. Current treatments typically show resistance after 18 months, highlighting the need for more effective therapies.